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Abstract 
Background: Atopy has been investigated as a potential risk factor for prostate cancer. IgE 
antibodies may be major players in protective responses against tumours, through 
engendering antigen presentation and enhancing adaptive immune responses targeted 
towards a specific allergen, but potentially also against tumour-associated antigens such as 
prostate-specific antigen (PSA). We therefore cross-sectionally investigated associations 
between circulating levels of PSA and IgE in the National Health and Nutrition Examination 
Survey 2005-2006. 
Methods: We focused on all men aged 40+ years with measurements for PSA and IgE, and 
no previous diagnosis of prostate cancer (n=1,312). We estimated the association between 
total and specific IgE concentration and levels of PSA with logistic regression models, 
adjusted for age, ethnicity/race, education, smoking status, body mass index (BMI), physical 
activity status, and history of asthma. 
Results: Both total IgE and the sum of specific IgE were inversely associated with the risk of 
having PSA levels ≥10 ng/ml, though most findings were not statistically significant. The 
odds ratios for the second and third tertile of total IgE as compared to the first were 0.21 
(95%CI: 0.06-0.72) and 0.42 (0.08-2.31). The odds ratio for sum of abnormal specific IgE 
measurements was 0.77 (0.44-1.34). 
Conclusion: Despite statistical insignificance, the observed trend warrants further research 
given the increasing evidence of the role of atopy and IgE antibodies in protective responses 
against tumours. A lifecourse approach of measuring IgE, specific subtypes, and other 
markers of the humoral immune system (i.e. IgG) could shed more light on its potential anti-
cancer characteristics. 
 
Key words: prostate cancer, IgE, PSA, atopy 
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Précis 
This cross-sectional analysis did not find a strong association between levels of total and 
specific IgE and PSA. However, given increasing evidence on the role of atopy in anti-
tumour activity, further research is needed.  
 
 
 
List of abbreviations 
BMI: Body mass index 
CI: Confidence interval 
HR: Hazard ratio 
NCHS: National Center for Health Statistics 
NHANES: National Health and Nutrition Examination Survey 
OR:  Odds ratio 
PSA: Prostate-specific antigen 
RR: Relative risk 
sIgE: Allergen-specific IgE 
tIgE: Total IgE 
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Introduction 
Atopy, defined as the propensity to develop IgE antibodies against environmental allergens, 
has been investigated as a potential risk factor for prostate cancer – with studies reporting 
positive associations as well as null findings [1-3]. A meta-analysis in 2009 concluded that 
the positive association of atopy, assessed by allergen-specific IgE (sIgE) or skin prick 
testing, with prostate cancer (relative risk [RR]: 1.43, 95% confidence interval [CI]: 1.08-
1.91) warrants further investigation [4]. Several studies have since investigated the link 
between allergies, asthma and prostate cancer. A Taiwanese cohort study of 12,372 men 
found that asthma increases the risk of prostate cancer (hazard ratio [HR]: 2.36, 95%CI: 
1.22-4.57) [5]. A Canadian case-control study also observed a positive association with ever 
reporting asthma, but no link with history of allergies [6]. Another Canadian cohort study 
based on 16,934 men also found a 25% increased risk of prostate cancer for men reporting 
a history of asthma [7]. Interestingly, the Health Professionals Follow-up Study, including 
798 lethal prostate cancer cases during 995,176 person-years, observed that ever having a 
diagnosis of asthma was inversely associated with risk of lethal or fatal prostate cancer [8]. 
Men with hay fever onset in the distant past were more likely to develop (fatal) prostate 
cancer. Currently, no explanation for the difference in the direction of the epidemiological 
associations for asthma and hay fever with prostate cancer has been proposed [8].  
 
From a biological perspective, there is also a need to further investigate IgE as an objective 
measurement of atopy in contrast to self-reported allergy data, and its potential role in 
prostate carcinogenesis. Prostate-specific antigen (PSA), which is detected in the serum of 
prostate cancer patients, has been widely evaluated for diagnostic and prognostic purposes, 
but recently also as a target of immunotherapy [9]. IgE antibodies may confer immunological 
protection against tumours by triggering antigen presentation and enhancing adaptive 
immune responses targeted towards specific allergens and possibly against tumour antigens 
such as PSA and therefore against PSA-expressing tumour cells [10]. The generation and 
persistence of memory T cells specific for homologous epitopes between allergens and 
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tumour antigens could also mediate anti-PSA effects and consequently anti-tumour 
protective functions, a concept that has received some attention in the field of allergy. For 
instance, the frequency of CD4+ T cells recognising epitopes of Can f 5, a dog-specific 
allergen, is 10-fold higher in allergic individuals and these cells are more likely to display IL-
5-highTh2-biased phenotypes [11]. If these cells cross-react with prostate cancer antigen 
peptides displayed on cancer cells, they could provide protective PSA-reactive immune 
surveillance.  
 
To further understand the role of atopy in the development of prostate cancer, we therefore 
cross-sectionally investigated the associations between circulating levels of PSA and IgE in 
the National Health and Nutrition Examination Survey (NHANES) 2005-2006 [12].   
 
Methods 
 
Study population 
 
Data was obtained from the NHANES 2005-2006, a national survey designed to assess the 
health and nutritional status of the civilian non-institutionalised US population [12]. In 1999, 
the survey became a continuous programme that has adaptable components on a variety of 
health and nutrition measurements to meet emerging needs. It examines a nationally 
representative sample of about 5,000 persons each year. These persons are located in 
counties across the country, 15 of which are visited each year. It was approved by the 
National Center for Health Statistics (NCHS) Research Ethics Review Board and all 
participants gave informed consent.  
 
All participants who completed a household interview were also invited to undergo Health 
Examination Components. Total IgE (tIgE) was measured in 94.1% of those aged 20 years 
or older and 92.4% also had data available for 19 different sIgE. For the current study, we 
focused on all men aged 40 years or older who had measurements for both PSA and IgE 
and had no previous diagnosis of prostate cancer (n=1,312). The latter was defined based 
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on questionnaire information related to prostate biopsies, cancer diagnoses, and PSA follow-
ups.  
 
Allergen-specific IgE and total IgE measurement 
The Pharmacia Diagnostics ImmunoCAP 1000 System was used to measure tIgE and sIgE. 
The latter was measured to a panel of 19 allergens [12]: Alternaria alternate, Apergillus 
fumigatus, Bermuda grass (Cynodon dactylon), birch (Betula verrucose), cat dander, 
cockroach (Blatella germanica), dog dander, dust mite (Dermatophagoides farina, D. 
pteronyssinus), egg white, milk, mouse urine proteins, oak (Quercus alba), peanut (Arachis 
hypgaea), ragweed (Ambrosia elatior), rat urine proteins, Russian thistle (Salsola kali), rye 
grass (Lolium perenne), and shrimp (Pandalus borealis). We assessed sIgE by the sum of 
positive sIgE according to their detection limit. We further categorised the total sum of sIgE 
into 0, 1-2, and 3+. Since tIgE was not normally distributed we transferred it into log10 units 
[13]. 
 
PSA measurements 
The Beckman Access Immunoassay System with the Hybritech Total PSA Assay (Beckman 
Coulter, Fullerton, CA) was used to measure serum levels of PSA (ng/mL) [12]. For the 
analyses, we dichotomised PSA based on the following values for abnormal levels: 
≥10ng/mL [14-16].  
 
Other covariates 
Other covariates were obtained from the questionnaire and physical examination data [12]. 
In addition to age, we included race/ethnicity (non-Hispanic white, non-Hispanic black, 
Mexican-American, and other), education (<9th grade, secondary school, and higher 
education), smoking status (current, former, never), body mass index (BMI; kg/m2), 
moderate or vigorous activity during the last 30 days (yes/no), and history of asthma 
(yes/no).  
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Statistical analyses 
Descriptive statistics were obtained for the total study population and by levels of circulating 
PSA (≥10 ng/nL). We calculated age-standardised proportions and means (based on 20-
year age groups of the 2000 US Census Standard Population). 
 
We then estimated the association between tIgE and sIgE and levels of PSA with univariate 
and multivariate logistic regression models. The latter were adjusted for age, ethnicity/race, 
education, smoking status, BMI, physical activity status, and history of asthma. We 
evaluated continuous levels and tertiles of tIgE and dichotomised and categorised levels of 
the sum of sIgE. An additional stratification by race/ethnicity was conducted, as well as by 
history of asthma. To provide further insight into the potential effects of different types of 
sIgE, we also looked into the proportion of positivity by PSA levels. 
 
All analyses were adjusted for the NHANES complex sampling design using Taylor series 
linearization methods through SAS statistical software (version 9.4, Cary, NC) survey 
procedures (surveyfreq, surveymeans, surveylogistic) according to the NHANES 
specifications.  
 
Results 
Out of 1,312 men 21 had levels of PSA≥10 ng/mL. They were slightly older than those with 
PSA <10 ng/mL and were more likely to be non-Hispanic white (91 vs 70%). Further 
differences in terms of education, smoking behaviour, and physical activity levels can be 
observed in Table 1. On average, their total IgE was higher, while their sum of sIgE was 
lower. 
 
Table 2 illustrates the odds ratio (OR) for having PSA levels ≥10ng/mL based on levels of 
total and specific IgE. Both were inversely associated with the risk of having PSA levels ≥10 
ng/ml, though most findings were not statistically significant. The ORs for the second and 
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third tertile of total IgE as compared to the first were: 0.21 (95%CI: 0.06-0.72) and 0.42 
(0.08-2.31), respectively. The OR for sum of abnormal specific IgE measurements was 0.77 
(95%CI: 0.44-1.34). 
 
The proportion of allergen-specific IgE by PSA levels is shown in Table 3. There was sIgE in 
both high and low PSA cohorts, with no clear patterns due to the rather small sample size. 
 
Additional stratification by ethnicity or history of asthma did not alter the above findings 
(results not shown).  
 
 
Discussion 
 
This cross-sectional analysis suggests a consistent inverse association between levels of 
total and specific IgE and levels of PSA, though none of the findings were statistically 
significant.  
 
Our findings do not support a strong association between IgE and PSA, and it is possible 
that potential links between allergic responses and the risk of developing PSA-producing 
prostate cancer may be more complex than any simple cause and effect relationship. It is 
possible that the disparities in reported associations [1-3] are manifestations of underlying 
immunological processes that may provide protection from the growth of prostate cancers in 
certain groups of individuals, but not in others. It can be envisaged then that stratifying 
particular individual groups based on allergic sensitization to specific allergens and 
autoantibodies to specific epitopes of these allergens may help delineate any such 
associations. This may also be the case for the relationship between IgE levels or allergies 
and PSA, and may consequently help us to identify any links between specific allergies in 
these patient groups and the risk of PSA-positive prostate cancer. 
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For instance, allergies to dog dander, also manifested by elevated IgE serum levels, have 
been associated with asthma prevalence and severity and allergic respiratory symptoms, 
including bronchial inflammation [17]. IgEs in patient sera are reported to recognise dog 
allergens such as the lipocalin family members (Can f 1, f 2, and f 4), the dog serum albumin 
Can f 3, which bears particular homology to human serum albumin [18-20], and the major 
dog allergen prostatic kallikrein, or Can f 5. Can f 5 has been identified in dog dander and 
urine and this protein is recognised by serum IgE antibodies from 70% of patients with dog 
allergies [21]. This allergen appears to share large structural similarities with human PSA, 
and anti-Can f 5 IgE antibodies in the blood of patients with dog allergies also appear to 
recognise human PSA [22]. This would support the notion that subsets of allergic individuals 
may also develop protective immune responses directed not only to allergens but also to 
tumour antigens. Such co-incidental cross-reactivities may in part explain some reported 
associations between allergies and lower levels of PSA. Consequently, an allergic response 
to particular allergenic molecules could provide a protective advantage that might explain a 
lower incidence of prostate cancer in only the subsets of individuals who develop antibodies 
to allergens that happen to cross-react with epitopes to tumour antigens. We found sIgE in 
both high and low PSA cohorts, with a proportion of IgE showing reactivity to dog allergens 
in both groups (Table 3). However, this dataset did not contain sufficient variation in data on 
dog dander, nor did it include detailed information on specific subtypes of dog allergens. 
These limitations, together with the low number of subjects with high PSA serum levels and 
lack of followup information on incidence of prostate cancer, do not permit interrogation of 
co-incidental antibody cross-reactivities to PSA and specific allergens or whether these 
might have any protective relevance.  
 
Future studies could benefit from longitudinal measurements of IgE, as some allergies may 
arise at a young age and could elicit strong immunological responses manifested by 
asthmatic symptoms, high IgE titres to allergens, as well as heightened cellular responses 
including eosinophil activation [23]. Therefore, it is tempting to speculate that development of 
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a strong allergic response to an allergen with high homology to a tumour antigen may 
provide long-term resistance to the growth of some cancers expressing this target antigen, 
specifically for this subset of allergic individuals. Recent findings of an inverse association 
between a diagnosis of asthma, rather than overall allergies or hay fever, and the risk of 
lethal prostate cancer [8], may lend merit to this possibility. 
 
Furthermore, future studies may contribute additional information on other markers of the 
humoral response. More specifically, the isotype of the antibodies raised to these allergens 
may not be confined to the IgE class and, therefore, different components of the humoral 
response should be delineated. Different antibody isotypes such as IgG1, known to provide 
immune activatory signals, IgG4 and IgA, which may be associated with long-term exposure 
to specific antigens or allergens [24-28], could also play key roles in immune surveillance. 
Activation of immune effector cells by a tumour antigen-specific IgE has recently been 
identified to trigger a cytokine signature known to occur in IgE-mediated clearance of 
parasitic infections [29]. It is then possible that the immunological context that could provide 
protection against tumour antigens may not be derived from atopy, but perhaps also from 
other conditions such as anti-parasitic responses, in which IgE, its effector cells, and Th2-
biased immune responses could play key roles. Therefore, a wider study of immunological 
surveillance against antigens, including those associated with cancer, could provide novel 
perspectives on what constitutes protection from carcinogenesis. 
 
This study has several strengths including its generalizibility following the use of nationally 
representative data. Therefore, it was also possible in our analysis to perform a stratified 
analysis by race/ethnicity. We were able to adjust for many potential confounding factors, 
but lacked information on prostate cancer diagnosis such that an increase in PSA 
measurements does not necessarily reflect carcinogenesis. Another limitation of this study is 
that it relies on one single measurement so that it may be prone to measurement error and 
within-person variation – with only 21 men having high levels of PSA. Repeated 
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measurements in a larger sample size may strengthen the accuracy of the direction of the 
association studied, so that it would be of interest to validate our findings in other population-
based settings. As this dataset did not contain information on prostate cancer diagnosis, the 
results of the current study should only be used to generate more hypotheses on the role of 
IgE in prostate carcinogenesis.  
 
Conclusion 
Even though our study did not find a strong inverse association between IgE and PSA, the 
trend of the indication warrants further research, given the increasing evidence on the role of 
atopy and IgE antibodies in protective responses against tumours. A lifecourse approach of 
measuring IgE, specific subtypes, and other markers of the humoral immune system (i.e. 
IgG), could shed more light on its potential anti-cancer characteristics. 
 
 
 
Conflict of interest: The authors declare that they have no conflict of interest. 
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Tables 
 
Table 1: Age-standardised weighted characteristics in men with PSA and IgE measurements in 
NHANES 2005-2006. 
 
 All PSA <10 
ng/ml 
PSA ≥10 
ng/ml Population (N, unweighted) 1312 1291 21 
Age (years; mean, SEM) 57.3, 0.3 57.3, 0.3 63.9, 0.6 
Race/ethnicity (%)    
Non-Hispanic white 78.99 79.02 91.14 
Non-Hispanic black 9.19 9.11 7.07 
Mexican-American 5.58 5.58 1.79 
Other 6.24 6.29 0.00 
Education (%)    
< 9th grade 8.59 8.41 30.84 
Secondary school 35.75 35.90 10.07 
Higher education 55.65 55.68 59.09 
BMI (kg/m2; mean, SEM) 29.1, 0.2 29.1, 0.2 23.3, 1.5 
.3 Cigarette smoking (%)    
Never 39.02 38.83 54.57 
Former 37.57 37.64 42.91 
Current  23.41 23.53 2.52 
History of asthma (%) 11.46 11.48 4.27 
Moderate or vigorous activity (%) 63.53 63.46 45.74 
PSA (ng/ml; mean, SEM) 1.6, 0.1 1.4, 0.1 20.4, 2.3 
Total IgE (kU/L; mean, SEM) 171.5, 14.2 172.6, 14.3 201.34, 
130.5 Allergen-specific IgE: ≥ 1 positive (%) 42.27 43.53 37.22
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Table 2: Unadjusted and adjusted odds ratios for the association between IgE and PSA≥10 ng/ml. 
 
 Unadjusted OR 
(95%CI) 
Adjusted OR^ 
(95%CI) 
Total IgE (per log10 changes) 0.66 (0.28-1.58) 0.70 (0.28-1.73) 
Total IgE (tertiles)   
<31.2 kU/L 1.00 (Ref) 1.00 (Ref) 
31.2-113 kU/L 0.27 (0.09-0.80) 0.21 (0.06-0.72) 
≥113 kU/L 0.45 (0.11-1.96) 0.42 (0.08-2.31) 
Allergen-specific IgE: ≥ 1 positive (%) 0.26 (0.07-0.92) 0.30 (0.08-1.18) 
^ Adjusted for age, ethnicity/race, education, smoking status, BMI, history of asthma, and physical activity 
status 
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Table 3: Proportion of allergen-specific IgE by PSA status. 
 
 PSA <10 ng/ml PSA ≥10 ng/ml 
Dust mite (Dermatophagoides farina) 5.17 6.09 
D. pteronyssinus 16.16 6.09 
Cat dander 12.01 4.14 
Dog dander 10.09 4.14 
Cockroach (Blatella germanica) 11.72 7.66 
Alternaria alternate 7.39 0.00 
Peanut (Arachis hypgaea) 7.57 0.00 
Egg white 3.26 3.50 
Milk 4.74 4.14 
Ragweed (Ambrosia elatior) 14.06 0.00 
Rye grass (Lolium perenne) 17.75 5.56 
Bermuda grass (Cynodon dactylon) 13.45 0.88 
Oak (Quercus alba) 9.58 0.00 
Birch (Betula verrucose) 9.45 0.00 
Shrimp (Pandalus borealis) 7.20 6.09 
Aspergillus fumigatus 5.87 4.14 
Russian thistle (Salsola kali) 9.78 0.00 
Mouse urine proteins 0.26 0.00 
Rat urine proteins 1.82 0.00 
 
